Literature DB >> 25599838

Thiol-derivatized minihepcidins retain biological activity.

Eileen Fung1, Kristine Chua1, Tomas Ganz1, Elizabeta Nemeth1, Piotr Ruchala2.   

Abstract

Minihepcidins are small peptides that mimic biological activity of the iron-regulatory hormone hepcidin. Structurally, they contain thiol-free-cysteine residue in position 7 which is crucial for their bioactivity. Nonetheless, free sulfhydryl group is not desirable in pharmaceutical entities as it may lead to dermatological side effects. Moreover free thiol moiety is quite reactive and depending on conditions/reagents may be alkylated and/or oxidized giving various Cys-derivatives: S-alkyl cysteines, sulfoxides, sulfones, disulfides, cysteinesulfinic and cysteic acids. To limit such reactivity and maintain bioactivity of minihepcidin(s) we used thiol-protection strategy based on activated vinyl thioethers. Novel S-protected analogs of physiologically active minihepcidin PR73 were synthesized and tested in vitro showing activity comparable to parental molecule. The most active compound, PR73SH was also tested in vivo showing activity profile analogous to PR73. Collectively, our findings suggest that S-vinyl-derivatization of minihepcidin(s) may be a suitable approach in the development of physiologically active agonists of hepcidin.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Iron; Minihepcidins; Peptides; S-alkylation of peptides

Mesh:

Substances:

Year:  2015        PMID: 25599838      PMCID: PMC4318710          DOI: 10.1016/j.bmcl.2014.12.094

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  22 in total

1.  A highly selective FRET-based fluorescent probe for detection of cysteine and homocysteine.

Authors:  Hoi-Yan Shiu; Hiu-Chi Chong; Yun-Chung Leung; Man-Kin Wong; Chi-Ming Che
Journal:  Chemistry       Date:  2010-03-15       Impact factor: 5.236

2.  Selective irreversible chemical tagging of cysteine with 3-arylpropiolonitriles.

Authors:  Oleksandr Koniev; Geoffray Leriche; Marc Nothisen; Jean-Serge Remy; Jean-Marc Strub; Christine Schaeffer-Reiss; Alain Van Dorsselaer; Rachid Baati; Alain Wagner
Journal:  Bioconjug Chem       Date:  2014-01-16       Impact factor: 4.774

3.  Minihepcidins prevent iron overload in a hepcidin-deficient mouse model of severe hemochromatosis.

Authors:  Emilio Ramos; Piotr Ruchala; Julia B Goodnough; Léon Kautz; Gloria C Preza; Elizabeta Nemeth; Tomas Ganz
Journal:  Blood       Date:  2012-09-18       Impact factor: 22.113

4.  The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis.

Authors:  Adriana Donovan; Christine A Lima; Jack L Pinkus; Geraldine S Pinkus; Leonard I Zon; Sylvie Robine; Nancy C Andrews
Journal:  Cell Metab       Date:  2005-03       Impact factor: 27.287

Review 5.  Hepcidin and disorders of iron metabolism.

Authors:  Tomas Ganz; Elizabeta Nemeth
Journal:  Annu Rev Med       Date:  2011       Impact factor: 13.739

Review 6.  Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation.

Authors:  Tomas Ganz
Journal:  Blood       Date:  2003-03-27       Impact factor: 22.113

7.  Sulfhydryl drug-induced eruption: a clinical and histological study.

Authors:  K Kitamura; M Aihara; J Osawa; S Naito; Z Ikezawa
Journal:  J Dermatol       Date:  1990-01       Impact factor: 4.005

8.  Gold-mediated selective cysteine modification of peptides using allenes.

Authors:  Anna On-Yee Chan; Johnson Lui-Lui Tsai; Vanessa Kar-Yan Lo; Gai-Li Li; Man-Kin Wong; Chi-Ming Che
Journal:  Chem Commun (Camb)       Date:  2013-02-18       Impact factor: 6.222

Review 9.  Manipulation of the hepcidin pathway for therapeutic purposes.

Authors:  Eileen Fung; Elizabeta Nemeth
Journal:  Haematologica       Date:  2013-11       Impact factor: 9.941

Review 10.  Hepcidin antagonists for potential treatments of disorders with hepcidin excess.

Authors:  Maura Poli; Michela Asperti; Paola Ruzzenenti; Maria Regoni; Paolo Arosio
Journal:  Front Pharmacol       Date:  2014-04-28       Impact factor: 5.810

View more
  6 in total

1.  Structure-function analysis of ferroportin defines the binding site and an alternative mechanism of action of hepcidin.

Authors:  Sharraya Aschemeyer; Bo Qiao; Deborah Stefanova; Erika V Valore; Albert C Sek; T Alex Ruwe; Kyle R Vieth; Grace Jung; Carla Casu; Stefano Rivella; Mika Jormakka; Bryan Mackenzie; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2017-12-13       Impact factor: 22.113

2.  Maternal hepcidin determines embryo iron homeostasis in mice.

Authors:  Veena Sangkhae; Allison L Fisher; Kristine J Chua; Piotr Ruchala; Tomas Ganz; Elizabeta Nemeth
Journal:  Blood       Date:  2020-11-05       Impact factor: 25.476

Review 3.  Hepcidin: A Promising Therapeutic Target for Iron Disorders: A Systematic Review.

Authors:  Jing Liu; Bingbing Sun; Huijun Yin; Sijin Liu
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

4.  Hepcidin deficiency and iron deficiency do not alter tuberculosis susceptibility in a murine M.tb infection model.

Authors:  Rachel Harrington-Kandt; Elena Stylianou; Lucy A Eddowes; Pei Jin Lim; Lisa Stockdale; Nawamin Pinpathomrat; Naomi Bull; Janet Pasricha; Marta Ulaszewska; Yulia Beglov; Sophie Vaulont; Hal Drakesmith; Helen McShane
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

Review 5.  Iron Therapeutics in Women's Health: Past, Present, and Future.

Authors:  Joel Mintz; Jackie Mirza; Eric Young; Kyle Bauckman
Journal:  Pharmaceuticals (Basel)       Date:  2020-12-08

6.  Identification of a novel Na+-coupled Fe3+-citrate transport system, distinct from mammalian INDY, for uptake of citrate in mammalian cells.

Authors:  Jiro Ogura; Ellappan Babu; Seiji Miyauchi; Sabarish Ramachandran; Elizebeta Nemeth; Yangzom D Bhutia; Vadivel Ganapathy
Journal:  Sci Rep       Date:  2018-02-06       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.